Chimerix’s Oncology Innovation Gains Prestigious Clinical Recognition

A Validation of Research Excellence

The inclusion of Modeyso (dordaviprone) in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines represents a significant validation for the oncology field. These guidelines are widely regarded as the gold standard for cancer care, providing evidence-based protocols for diagnosis and therapeutic approaches. The specific recommendation covers the treatment of H3 K27M-mutant diffuse midline glioma, a rare and highly aggressive form of brain cancer.

This development serves as a powerful endorsement of Chimerix’s drug development capabilities. Although Jazz Pharmaceuticals completed its acquisition of Modeyso in April 2025, the therapeutic candidate originated from Chimerix’s research pipeline. The rigorous evaluation process required for NCCN inclusion validates the company’s foundational science and clinical development work.